Bulevirtide plus Tenofovir Disoproxil Fumarate Improves Liver Function in HDV/HBV Related Cirrhosis after Virological Response: A Case Report

Bulevirtide plus Tenofovir Disoproxil Fumarate Improves Liver Function in HDV/HBV Related Cirrhosis after Virological Response: A Case Report

Hepatitis D virus (HDV) globally affects nearly 5% of people with chronic hepatitis B virus (HBV) infection. Bulevirtide (BLV) is an HDV/HBV entry inhibitor recently approved for adult patients with chronic hepatitis delta (CHD). In this real-life case report, we describe the virological efficacy, t...

Full description

Bibliographic Details
Main Authors:	Nikolaos Papadopoulos, Panagiotis Tsibouris, Ioannis Braimakis, Periklis Apostolopoulos
Format:	Article
Language:	English
Published:	MDPI AG 2022-10-01
Series:	Gastrointestinal Disorders
Subjects:	hepatitis D virus hepatitis B virus chronic hepatitis delta
Online Access:	https://www.mdpi.com/2624-5647/4/4/26

Similar Items

Broad-spectrum activity of bulevirtide against clinical isolates of HDV and recombinant pan-genotypic combinations of HBV/HDV
by: Roberto Mateo, et al.
Published: (2023-11-01)

Modeling the Interplay between HDV and HBV in Chronic HDV/HBV Patients
by: Adequate Mhlanga, et al.
Published: (2022-10-01)

Molecular and Clinical Features of Hepatocellular Carcinoma in Patients with HBV-HDV Infection
by: Costante F, et al.
Published: (2023-04-01)

Efficacy and Safety of Bulevirtide plus Tenofovir Disoproxil Fumarate in Real-World Patients with Chronic Hepatitis B and D Co-Infection
by: Toni Herta, et al.
Published: (2022-04-01)

Characterization of the Full-Length Genome Sequences and Phylogenetic Analysis of HDV Strains Isolated from Patients with Chronic HBV and HDV Infection in Kyrgyz Republic
by: Yu. V. Ostankova, et al.
Published: (2020-04-01)

The genotoxicity of Tenofovir disoproxil fumarate in HBV-infected patients
by: Selcen Korkmaz, et al.
Published: (2018-09-01)

A Mathematical Model for Early HBV and -HDV Kinetics during Anti-HDV Treatment
by: Rami Zakh, et al.
Published: (2021-12-01)

Renal and bone side effects of long-term use of entecavir, tenofovir disoproxil fumarate, and tenofovir alafenamide fumarate in patients with Hepatitis B: a network meta-analysis
by: Zekun Liu, et al.
Published: (2023-11-01)

Constraint of Base Pairing on HDV Genome Evolution
by: Saki Nagata, et al.
Published: (2021-11-01)

Is Combined Bulevirtide and Pegylated Interferon Therapy for Chronic Hepatitis D Superior over Bulevirtide Monotherapy?
by: V. E. Syutkin, et al.
Published: (2020-09-01)

Predominance of HBV Genotype B and HDV Genotype 1 in Vietnamese Patients with Chronic Hepatitis
by: Nghiem Xuan Hoan, et al.
Published: (2021-02-01)

HDV Seroprevalence in HBsAg-Positive Patients in China Occurs in Hotspots and Is Not Associated with HCV Mono-Infection
by: Imme Roggenbach, et al.
Published: (2021-09-01)

HDV Pathogenesis: Unravelling Ariadne’s Thread
by: Eirini D. Tseligka, et al.
Published: (2021-04-01)

Seroprevalence of HBsAg, Anti-HBs, anti-HDV and HDVAg in Inonu University Medical Faculty Hospital, 2012 [Inonu Universitesi Tip Fakultesi Hastanesinde, 2012 Yilinda, HBsAg, Anti-HBs, Anti-HDV ve HDVAg Seroprevalansi]
by: Yucel Duman, et al.
Published: (2014-03-01)

The Prevalence and Risk Factors of Hepatitis Delta Virus in HIV/HBV Co-Infected Patients in Shiraz, Iran, 2012
by: Mohammad Motamedifar, et al.
Published: (2015-09-01)

Role of tenofovir disoproxil fumarate in prevention of perinatal transmission of hepatitis B virus from mother to child: a systematic review and meta-analysis
by: Young-Sun Lee, et al.
Published: (2021-01-01)

Apulian infectious diseases network: survey on the prevalence of delta infection among chronic HBV carriers in Apulia
by: Massimo Fasano, et al.
Published: (2023-09-01)

Genetic diversity of HBV in indigenous populations on the border between Brazil and Bolivia
by: Fabianne Araújo Gomes dos Santos Alves, et al.
Published: (2022-09-01)

Long-term follow-up of patients discontinuing bulevirtide treatment upon long-term HDV-RNA suppression
by: Mathias Jachs, et al.
Published: (2023-08-01)

Hepatitis Flares or Hepatic Decompensation after Discontinuation of Tenofovir Disoproxil Fumarate and Entecavir in Non-Cirrhotic Hepatitis B e Antigen-Negative Patients
by: Yi-Jie Huang, et al.
Published: (2023-12-01)

Standard and pegylated interferon therapy of HDV infection: A systematic review and meta- analysis
by: Seyed-Moayed Alavian, et al.
Published: (2012-01-01)

Animal delta-like viruses (Kolmioviridae: Deltavirus) and the origin of the human hepatitis D virus (HDV)
by: O. V. Isaeva, et al.
Published: (2021-11-01)

Week 96 Results of Switching from Tenofovir Disoproxil Fumarate-Based Antiretroviral Therapy to Coformulated Elvitegravir, Cobicistat, Emtricitabine, and Tenofovir Alafenamide among HIV/Hepatitis B Virus-Coinfected Patients
by: Yu-Shan Huang, et al.
Published: (2023-06-01)

Delta Hepatitis Positivity in Hepatitis B Virus Infected Patients; Coinfection or Superinfection?
by: Özlem Aydemir, et al.
Published: (2019-06-01)

Comparison of Pegylated Interferon Alfa Therapy in Combination with Tenofovir Alafenamide Fumarate or Tenofovir Disoproxil Fumarate for Treatment of Chronic Hepatitis B Patients
by: He J, et al.
Published: (2023-06-01)

A Review of HDV Infection
by: Gian Paolo Caviglia, et al.
Published: (2022-08-01)

Epidemiology of Viral Hepatitis in the Indigenous Populations of the Arctic Zone of the Republic of Sakha (Yakutia)
by: Vera S. Kichatova, et al.
Published: (2024-02-01)

Simulation on The Mathematical Model for the Control Of Hepatitis B Virus-Hepatitis D Virus (HBV-HDV) Co-infection Transmission Dynamics in a Given Population
by: Remigius Okeke Aja, et al.
Published: (2021-08-01)

Epidemiology of the Hepatitis D virus
by: Mario Rizzetto
Published: (2020-03-01)

Prevalence of hepatitis delta virus infection among hepatitis B virus-infected and exposed patients
by: Krithiga Ramachandran, et al.
Published: (2020-01-01)

Inhibitory Effect of IL-1β on HBV and HDV Replication and HBs Antigen-Dependent Modulation of Its Secretion by Macrophages
by: Marion Delphin, et al.
Published: (2021-12-01)

Liver stiffness measurement at complete virological response in hepatoma prediction for HBV‐related cirrhosis patient with potent antiviral agent
by: Jing‐Houng Wang, et al.
Published: (2019-11-01)

Insight into the Contribution and Disruption of Host Processes during HDV Replication
by: Gabrielle Goodrum, et al.
Published: (2018-12-01)

Efficacy of long-term tenofovir disoproxil fumarate therapy in chronic hepatitis B patients with partial virologic response in real practice
by: Jeong Eun Song, et al.
Published: (2019-07-01)

HGV-HCV/HBV co-infection in India: A pilot study
by: Amruta D Pathare, et al.
Published: (2013-01-01)

Treatment of patients with HBV cirrhosis: Successes, unsolved problems
by: I G Bakulin, et al.
Published: (2013-12-01)

Effect of entecavir and tenofovir disoproxil fumarate on hepatocellular carcinoma in subjects with chronic hepatitis B: a meta-analysis
by: Sara M. Tony, et al.
Published: (2022-09-01)

New biomarkers of hepatitis B virus (HBV) infection: HBV RNA and HBV core-related antigen, new kids on the block?
by: Young-Suk Lim
Published: (2023-01-01)

Short-term and long-term safety and efficacy of tenofovir alafenamide, tenofovir disoproxil fumarate and entecavir treatment of acute-on-chronic liver failure associated with hepatitis B
by: Juan Li, et al.
Published: (2021-06-01)

Bulevirtide in the Treatment of Hepatitis Delta: Drug Discovery, Clinical Development and Place in Therapy
by: Soriano V, et al.
Published: (2023-01-01)